B. Jouaneton

Medicine · Health Sciences

9h-index374citations46works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(16), Lung Cancer Treatments and Mutations(10), Economic and Financial Impacts of Cancer(10), Business Process Modeling and Analysis(8), Healthcare Systems and Practices(6)

Publications46 total

Characteristics, management, and healthcare resources of patients with advanced non–small-cell lung cancer surviving 5 years after nivolumab treatment initiation: A national database analysis
Respiratory Medicine and Research·2023· 1 citedOpen Access
Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting
Therapeutic Advances in Medical Oncology·2023· 5 citedOpen Access
Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France
Journal of Medical Economics·2022· 2 citedOpen Access
POSC418 Long-Term Evolution of Hospital Resource Utilization and Associated Costs Using Adjustment Methods: in Patients Treated with Nivolumab for Advanced Non-Small Cell Lung Cancer
Value in Health·2022
POSA235 Immune Checkpoint Inhibitors (ICI) Infusion at Home for Cancer Patients: An Analysis of the French National Hospital Database (PMSI)
Value in Health·2022
101P Nivolumab outcomes in interstitial lung disease patients with advanced non-small cell lung cancer in French real-world setting
Annals of Oncology·2021· 1 citedOpen Access
PCN348 Long-Term Healthcare Resource Utilization and Costs Associated with Patients Treated with Nivolumab for Advanced Non-Small Cell Lung Cancer
Value in Health·2020
PCN138 Study of the Burden of Blood Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes Who Receive Regular Transfusions
Value in Health·2020· 1 citedOpen Access
PCN350 Treatment Sequences of Patients Surviving at Least Two Years after Initiation of Nivolumab in Previously Treated Advanced Non-Small Cell Lung Cancer (aNSCLC): Contribution of Time-Sequence K-Clustering Analysis
Value in Health·2020
Automatic and Explainable Labeling of Medical Event Logs With Autoencoding
IEEE Journal of Biomedical and Health Informatics·2020· 14 cited
1276P Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): Real-world 3-year outcomes within overall and special populations (the UNIVOC study)
Annals of Oncology·2020· 1 citedOpen Access
Prise en charge des patients avec un cancer bronchique avancé et vivants deux ans après un traitement par nivolumab en deuxième ligne ou plus : intérêt des techniques de « Machine learning »
Revue d Épidémiologie et de Santé Publique·2020
An optimization-based process mining approach for explainable classification of timed event logs
2020· 5 citedOpen Access
Optimal process mining of timed event logs
Information Sciences·2020· 19 cited
Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study)
Therapeutic Advances in Medical Oncology·2020· 19 citedOpen Access
Nivolumab dans le cancer du poumon non à petites cellules (CBNPC) à un stade avancé : résultats d’une cohorte rétrospective nationale française (étude UNIVOC)
Revue des Maladies Respiratoires Actualités·2020
Efficacité en vie réelle de nivolumab chez les patients octogénaires atteints d’un cancer bronchique non à petites cellules au stade avancé en France (étude UNIVOC)
Revue des Maladies Respiratoires Actualités·2020
Re-challenge de l’immunothérapie en vie réelle après un traitement par nivolumab dans le traitement du cancer bronchique non à petites cellules (CBNPC) à un stade avancé en France (étude UNIVOC)
Revue des Maladies Respiratoires Actualités·2020
Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis
Lung Cancer·2019· 123 citedOpen Access
PCN507 CAN TRANSFERABILITY OF CLINICAL TRIALS POPULATION TO REAL WORLD SETTING BE ASSESSED USING FRENCH NATIONAL HEALTHCARE DATABASE? A CASE STUDY IN ONCOLOGY
Value in Health·2019Open Access
page 1 of 3Next →

Frequent Co-authors

C. Chouaïd(19), V. Grumberg(17), R. Jolivel(14), Jean‐Baptiste Assié(14), Matteo Giaj Levra(12), François-Emery Cotté(12), R. Corre(12), C. Calvet(12), Alexandre Vainchtock(12), Anne-Françoise Gaudin(11), A.F. Gaudin(10), Martin Prodel(8), Vincent Augusto(8), FE Cotté(8), Ludovic Lamarsalle(7), Xiaolan Xie(7), L. de Léotoing(5), D. Reynaud(5), Hugo De Oliveira(3), J-B. Assié(3)